No products in the cart.
BLOOD
Plasma and buffy coat
Banked plasma and matched buffy coat for comparison with the same donor’s tumor tissue. The team reviews collection and processing records against your analyte and assay requirements.
LIQUID BIOPSY & MCED
A liquid biopsy is only as good as the cohort behind it.
Patient-matched plasma, buffy coat, and tumor tissue for liquid biopsy and oncology biomarker research. Source banked sets or plan a collection around your cohort, treatment status, and protocol.
Explore matched sets
WHAT WE DO
We bring the patients to your study.
Liquid biopsy development and oncology biomarker research depend on access to patients across disease stages, treatment histories, and demographic groups. Study cohorts should reflect the population your diagnostic or therapy is intended to serve.
Our physician network recruits and collects to your protocol. You define the cohort; we connect your study with eligible patients and coordinate specimen collection.
MATCHED SPECIMEN SETS
Compare biomarker signals in blood and tumor.
Patient-matched specimens let you compare findings across plasma, buffy coat, and tumor tissue from the same donor, supporting biomarker discovery, concordance studies, and oncology drug development.
TUMOR TISSUE
FFPE and frozen tissue
FFPE tumor tissue for histologic and molecular assessment, with frozen tissue included in selected sets. Compare tissue findings with the matched plasma result.
Available matched specimen sets
Selected inventory by cancer diagnosis and specimen type. Download the full workbook for donor-level details and quantities.
| Clinical diagnosisRecorded pathology | Blood | Tumor tissue | ||
|---|---|---|---|---|
| Plasma | Buffy coat | FFPE tissue | Frozen tissue | |
| Breast CancerInvasive Ductal Carcinoma (IDC) | Plasma | Buffy coat | FFPE tissue | Frozen tissue |
| Colorectal CancerAdenocarcinoma | Plasma | Buffy coat | FFPE tissue | Frozen tissue |
| Ovarian CancerPapillary Cystoadenocarcinoma | Plasma | Buffy coat | FFPE tissue | Frozen tissue |
| Prostate CancerAdenocarcinoma | Plasma | Buffy coat | FFPE tissue | Frozen tissue Not listed |
| Renal cancerClear Cell Carcinoma | Plasma | Buffy coat | FFPE tissue | Frozen tissueNot listed |
| LymphomaNon-Hodgkin's Lymphoma | Plasma | Buffy coat | FFPE tissue | Frozen tissue |
Breast Cancer
Invasive Ductal Carcinoma (IDC)
Blood
PlasmaBuffy coatTumor tissue
FFPE tissueFrozen tissueColorectal Cancer
Adenocarcinoma
Blood
PlasmaBuffy coatTumor tissue
FFPE tissueFrozen tissueOvarian Cancer
Papillary Cystoadenocarcinoma
Blood
PlasmaBuffy coatTumor tissue
FFPE tissueFrozen tissueProstate Cancer
Adenocarcinoma
Blood
PlasmaBuffy coatTumor tissue
FFPE tissueFrozen tissueNot listedRenal cancer
Clear Cell Carcinoma
Blood
PlasmaBuffy coatTumor tissue
FFPE tissueFrozen tissueNot listedLymphoma
Non-Hodgkin's Lymphoma
Blood
PlasmaBuffy coatTumor tissue
FFPE tissueFrozen tissueListed in selected setNot listed in selected setIndividual sets differ. Availability, quantities, and case details are confirmed for each request.
COHORT DESIGN
Design the comparison your assay needs.
For early-detection work, define healthy, benign, and cancer cohorts around the intended-use population. We scope eligibility and collection for each group.
Healthy
Reference comparisons
Define eligibility and clinical-review criteria for reference specimens used to assess false-positive rates.
Benign
Nonmalignant conditions
Include relevant benign conditions to evaluate how the assay distinguishes them from cancer-associated findings.
Cancer
Disease-associated findings
Define cohorts by indication, stage, and treatment status to study the signals your assay measures.
Shared cohort criteria
- Age, gender, and ethnicity
- Treatment status
- Collection
- Handling
Define demographic matching and treatment-naive requirements across the cohorts. Plan consistent collection and handling to reduce pre-analytical variation.
CUSTOM COLLECTION
Define the collection around your study.
Work with the Biospecimen Solutions team to plan a direct collection through our physician network in the United States and Latin America. For tumor-adjacent normal tissue, other specimen types, or different combinations, we scope a protocol-specific collection.
Cohort design
Indication, stage, treatment status, and donor demographics, including requirements for treatment-naive cohorts.
Pre-analytical controls
Tube type, processing windows, centrifugation, and storage, specified for the analyte and assay. Discuss requirements for ctDNA, cfRNA, methylation, and fragmentomics.
Study data
Required clinical fields, collection timepoints, blood-to-tissue timing, and pathology review, captured per protocol.
Indications for collection planning
Discuss your protocol for these and other indications.
- NSCLC
- Breast
- Colorectal
- Prostate
- Ovarian
- Pancreatic
- Bladder
- Hepatocellular
- Gastric/GEJ
- Head and neck
Recorded data for specimen selection
Clinical profile
Diagnosis, histology, tumor grade, and stage.
Donor profile
Age, gender, and ethnicity, as recorded in the inventory.
Specimen details
Specimen type, collection date, and recorded quantity.
Direct collections follow IRB/IEC oversight, informed consent, and documented chain of custody. De-identified specimens and clinical data are supplied according to the agreed protocol.
EXPERIENCE
Experience supporting liquid biopsy development.
Work with a biospecimens team experienced in the collection requirements, clinical data, and specimen handling that diagnostic and drug development demand.
Biospecimens team experience
20+
Years in biospecimens
9M+
Specimens
800+
Programs
DCN Dx maintains ISO 13485- and ISO 9001-certified quality systems.
REQUEST SPECIMENS
Tell us about your liquid biopsy program.
Share your indication, specimen types, cohort criteria, quantities, and timing. The team will review banked matched sets or plan a direct collection.
Loading inquiry form…
Include stage, treatment status, or donor criteria, if relevant.
Please enter the specimen types you need.